Price (delayed)
$12.51
Market cap
$72.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$25.78
Enterprise value
$98.28M
Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers
There are no recent dividends present for ATRA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.